EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Vaccine Development to Treat Alzheimer’s Disease Neuropathology in APP/PS1 Transgenic Mice

Iván Carrera, Ignacio Etcheverría, Lucía Fernández-Novoa, Valter Lombardi, Ramón Cacabelos, Carmen Vigo

International Journal of Alzheimer's Disease · 2012 · 2012 · 1-17

DOI: 10.1155/2012/376138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Alzheimer's Disease, 2012. Verfasst von Iván Carrera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, EuroEspes Biotechnology, Polígono de Bergondo, Nave F, 15165 A Coruña, Spain. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel vaccine addressing the major hallmarks of Alzheimer’s disease (AD), senile plaque-like deposits of amyloid beta-protein (A β ), neurofibrillary tangle-like structures, and glial proinflammatory cytokines, has been developed. The present vaccine takes a new approach to circumvent failures of previous ones tested in mice and humans, including the Elan-Wyeth vaccine (AN1792), which caused massive T-cell activation, resulting in a meningoencephalitis-like reaction. The EB101 vaccine consists of A β 1 - 42 delivered in a novel immunogen-adjuvant composed of liposomes-containing sphingosine-1-phosphate (S1P). EB101 was administered to APPswe/PS1dE9 transgenic mice before and after AD-like pathological symptoms were detectable. Treatment with EB101 results in a marked reduction of A β plaque burden, decrease of neurofibrillary tangle-like structure density, and attenuation of astrocytosis. In this transgenic mouse model, EB101 reduces the basal immunological interaction between the T cells and immune activation markers in the affected hippocampal/cortical areas, consistent with decreased amyloidosis-induced inflammation. Therefore, immunization with EB101 prevents and reverses AD-like neuropathology in a significant manner by halting disease progression without developing behavioral spatial deficits in transgenic mice.

Autor:innen und Institutionen

  • Department of Neurosciences, EuroEspes Biotechnology, Polígono de Bergondo, Nave F, 15165 A Coruña, Spain.

Zitieren

APA

Carrera, I., Etcheverría, I., Fernández-Novoa, L., Lombardi, V., Cacabelos, R., & Vigo, C. (2012). Vaccine Development to Treat Alzheimer’s Disease Neuropathology in APP/PS1 Transgenic Mice. International Journal of Alzheimer's Disease, 2012, 1-17. https://doi.org/10.1155/2012/376138

Vancouver

Carrera I, Etcheverría I, Fernández-Novoa L, Lombardi V, Cacabelos R, Vigo C. Vaccine Development to Treat Alzheimer’s Disease Neuropathology in APP/PS1 Transgenic Mice. International Journal of Alzheimer's Disease. 2012;2012:1-17. doi:10.1155/2012/376138

BibTeX
@article{Carrera2012,
  author = {Carrera, Iván and Etcheverría, Ignacio and Fernández-Novoa, Lucía and Lombardi, Valter and Cacabelos, Ramón and Vigo, Carmen},
  title = {Vaccine Development to Treat Alzheimer’s Disease Neuropathology in APP/PS1 Transgenic Mice},
  journal = {International Journal of Alzheimer's Disease},
  year = {2012},
  volume = {2012},
  pages = {1--17},
  doi = {10.1155/2012/376138}
}
Kostenlos starten →